SCM
BCRX icon

Sio Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Sio Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-38,700
Closed -$147K – 67
2019
Q2 		$147K Buy
+38,700
New +$233K 0.04% 70

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Sio Capital Management's BCRX Position: Q3 2019 in Review

Sio Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2019, closing a stake of 522,863 shares — an estimated $1.98M sold.

Sio Capital Management first reported a position in BCRX in Q2 2019 and held it in 1 quarter. The position peaked at $1.98M in Q2 2019. 115 funds tracked by Wall St. Rank hold BCRX as of Q3 2019.

  • Sio Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Sio Capital Management sold 522,863 BioCryst Pharmaceuticals shares in Q3 2019, an estimated $1.98M.
  • Sio Capital Management first reported a position in BioCryst Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • Sio Capital Management's BioCryst Pharmaceuticals position peaked at $1.98M in Q2 2019.
  • 115 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2019.

Based on Sio Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.